Fig. 6: P53 exerts its effects on bone mass by promoting Nedd4 promoter activity.
From: Beraprost ameliorates postmenopausal osteoporosis by regulating Nedd4-induced Runx2 ubiquitination
A Schematic illustration of the p53-binding sequence and the promoter region of Nedd4 in mice and humans. B, C P53 binds to its binding sites in the Nedd4 promoter, as shown by the ChIP assay. Results are shown as mean ± SD; n = 5; ***P < 0.001 by analysis of variance (ANOVA) with Tukey’s post-hoc test. D Mutations in the putative p53-binding site in the Nedd4 promoter region. E Mutations in the binding site decreased luciferase activity in M-BMSCs. Results are shown as mean ± SD; n = 5; *P < 0.05, **P < 0.01, and ***P < 0.001 by ANOVA with Tukey’s post-hoc test. F–I qRT-PCR and western blotting were used to measure the transfection efficiency of Nedd4 in M-BMSCs and MC3T3-E1 cells. n = 5; ***P < 0.001 by ANOVA with Tukey’s post-hoc test. J, K Quantitative analysis of ALP activity. n = 5; *P < 0.05, **P < 0.01, and ***P < 0.001 by ANOVA with Tukey’s post-hoc test. L, M qRT-PCR showing mRNA expression of Runx2, Alp, OCN, and OSX in M-BMSCs. Results are shown as mean ± SD; n = 5; ns (P > 0.05), **P < 0.01 and ***P < 0.001 by ANOVA with Tukey’s post-hoc test. N Representative images of ALP and ARS staining.
